150 related articles for article (PubMed ID: 2149285)
1. Phase III studies of toremifene in metastatic breast cancer.
Pyrhönen SO
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S41-6. PubMed ID: 2149285
[TBL] [Abstract][Full Text] [Related]
2. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
Hietanen T; Baltina D; Johansson R; Numminen S; Hakala T; Helle L; Valavaara R
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S37-40. PubMed ID: 2149284
[TBL] [Abstract][Full Text] [Related]
3. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
Konstantinova MM; Gershanovich MA
Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
Modig H; Borgström S; Nilsson I; Westman G
J Steroid Biochem; 1990 Jun; 36(3):237-8. PubMed ID: 2142243
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
Bishop J; Murray R; Webster L; Pitt P; Stokes K; Fennessy A; Olver I; Leber G
Cancer Chemother Pharmacol; 1992; 30(3):174-8. PubMed ID: 1385761
[TBL] [Abstract][Full Text] [Related]
6. Phase II trials with toremifene in advanced breast cancer: a review.
Valavaara R
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
[TBL] [Abstract][Full Text] [Related]
7. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
Gundersen S
J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
[TBL] [Abstract][Full Text] [Related]
8. Current status of toremifene, a new antiestrogenic agent for the treatment of breast cancer. A symposium. San Antonio, TX, USA, December 7, 1989.
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S1-54. PubMed ID: 1980832
[No Abstract] [Full Text] [Related]
9. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
Pyrhönen S; Valavaara R; Heikkinen M; Rissanen P; Blanco G; Nordman E; Holsti LR; Hajba A
J Steroid Biochem; 1990 Jun; 36(3):227-8. PubMed ID: 2142239
[TBL] [Abstract][Full Text] [Related]
10. Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel CL
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):9-13. PubMed ID: 9556785
[TBL] [Abstract][Full Text] [Related]
11. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.
Gershanovich M; Garin A; Baltina D; Kurvet A; Kangas L; Ellmén J
Breast Cancer Res Treat; 1997 Sep; 45(3):251-62. PubMed ID: 9386869
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Breast Cancer Res Treat; 2001 Jan; 65(2):119-24. PubMed ID: 11261827
[TBL] [Abstract][Full Text] [Related]
13. Effect of toremifene in breast cancer patients. Preliminary communication.
Hindy I; Juhos E; Szántó J; Számel I
J Steroid Biochem; 1990 Jun; 36(3):225-6. PubMed ID: 2142238
[TBL] [Abstract][Full Text] [Related]
14. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Thölix E; Nordman E; Taskinen P; Holsti L; Hajba A
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):785-90. PubMed ID: 2968265
[TBL] [Abstract][Full Text] [Related]
15. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication.
Ebbs SR; Roberts J; Baum M
J Steroid Biochem; 1990 Jun; 36(3):239. PubMed ID: 2142244
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.
Modig H; Borgström S; Nilsson I; Westman G
J Steroid Biochem; 1990 Jun; 36(3):235-6. PubMed ID: 2142242
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
[TBL] [Abstract][Full Text] [Related]
19. The significance of estrogen receptors in tamoxifen and toremifene therapy.
Valavaara R; Kangas L
Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
[TBL] [Abstract][Full Text] [Related]
20. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
